ITAY PATYA
- Is Oramed bringing the gospel to diabetes patients? The company is developing oral insulinThe company's stock shot upwards by 38% on Wall Street to 4.5$ and in Tel Aviv; H.C Wainwright & Co. gave a 17 dollar price target – 3.5 times more than the market; head of R&D, Miriam Kadron – "I'm no analyst, but 17 dollars is pretty low if the development is a success".
